Ambee Pharmaceuticals PLC

DSE:AMBEEPHA Stock Report

Market Cap: ৳1.7b

Ambee Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

Ambee Pharmaceuticals has been growing earnings at an average annual rate of 19.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 13.3% per year. Ambee Pharmaceuticals's return on equity is 43.5%, and it has net margins of 5.2%.

Key information

19.1%

Earnings growth rate

19.1%

EPS growth rate

Pharmaceuticals Industry Growth11.0%
Revenue growth rate-13.3%
Return on equity43.5%
Net Margin5.2%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ambee Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DSE:AMBEEPHA Revenue, expenses and earnings (BDT Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2420511970
31 Dec 2320911990
30 Sep 2320810980
30 Jun 231989920
31 Mar 2319110870
31 Dec 221809820
30 Sep 221868850
30 Jun 221818830
31 Mar 22134-13640
31 Dec 21136-13650
30 Sep 21109-13520
30 Jun 2199-13480
31 Mar 21147-1740
31 Dec 201881960
30 Sep 2024121180
30 Jun 2028541400
31 Mar 2031131450
31 Dec 1931631470
30 Sep 1931331460
30 Jun 1932131490
31 Mar 1933681610
31 Dec 1834491660
30 Sep 1834781670
30 Jun 1834981660
31 Mar 1835081610
31 Dec 1735281590
30 Sep 1735581600
30 Jun 1735271590
31 Mar 1735251680
31 Dec 1633741600
30 Sep 1634031600
30 Jun 1634151600
30 Sep 1534871540
30 Jun 1536681670
31 Mar 1534971580
31 Dec 1434481560

Quality Earnings: AMBEEPHA has high quality earnings.

Growing Profit Margin: AMBEEPHA's current net profit margins (5.2%) are higher than last year (5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AMBEEPHA's earnings have grown by 19.1% per year over the past 5 years.

Accelerating Growth: AMBEEPHA's earnings growth over the past year (12.4%) is below its 5-year average (19.1% per year).

Earnings vs Industry: AMBEEPHA earnings growth over the past year (12.4%) exceeded the Pharmaceuticals industry -2.2%.


Return on Equity

High ROE: Whilst AMBEEPHA's Return on Equity (43.5%) is outstanding, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies